These findings support the hypothesis that increasing GCase activity reduces α-synuclein levels in dopaminergic neurons, and has significant implications for the use of GCase chaperones as treatments to reduce α-synuclein in PD patients. The gene discussed is SNCA; the disease is Parkinson disease.